Literature DB >> 15541986

Lung adenocarcinoma can be subtyped according to tumor dimension by computed tomography mediastinal-window setting. Additional size criteria for clinical T1 adenocarcinoma.

Yukinori Sakao1, Takahiko Nakazono, Shinji Tomimitsu, Yuji Takeda, Toru Sakuragi, Masafumi Natsuaki, Tsuyoshi Itoh.   

Abstract

OBJECTIVE: We sought to verify that the size of the solid component, which can be evaluated using the computed tomography mediastinal-window setting, provides new criteria for CT classification of lung adenocarcinoma.
METHODS: Between 1994 and September 2002, we examined 60 patients who were clinically classified with stage T1 adenocarcinoma of the lung and normal serum CEA, who underwent standard surgical procedures. Tumor maximum dimension was evaluated using two different CT-imaging settings: the lung window (lDmax), and the mediastinal window (mDmax). We analyzed the relationships between prognosis or lymph node involvement and tumor dimensions.
RESULTS: The mDmax was a significant (OR 1.11, P=0.02) predictive factor for lymph node metastasis. However, lDmax was not significant (P=0.83). Age, gender, lDmax, mDmax, and lymph node involvement were analyzed as predictive factors for prognosis. In univariate analysis, mDmax and lymph node involvement were significant predictive factors for prognosis (OR 1.07, P=0.01; OR 2.56, P=0.04; respectively). In multivariate analysis, mDmax was a significant predictive factor for prognosis (OR 1.06, P=0.04). We then classified the C-T1 adenocarcinoma patients into three groups according to mDmax: T1a (< or =10 mm), T1b (from 11 to 20 mm), and T1c (from 21 to 30 mm). There was a significant difference between the three groups: the disease-free 5-year survivals were 93.3, 58.1, and 32.7%, respectively (P=0.01).
CONCLUSIONS: The mDmax can give additional, useful prognostic data. This finding may provide new criteria for CT classification of lung adenocarcinoma.

Entities:  

Mesh:

Year:  2004        PMID: 15541986     DOI: 10.1016/j.ejcts.2004.08.021

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  11 in total

1.  Evidence based imaging strategies for solitary pulmonary nodule.

Authors:  Yi-Xiang J Wang; Jing-Shan Gong; Kenji Suzuki; Sameh K Morcos
Journal:  J Thorac Dis       Date:  2014-07       Impact factor: 2.895

2.  Simple preoperative computed tomography image analysis shows good predictive performance for pathological vessel invasion in clinical stage IA non-small cell lung cancer.

Authors:  Takuya Ito; Tomohiro Murakawa; Hajime Sato; Aska Tanabe; Masaki Maekawa; Yukihiro Yoshida; Masashi Fukayama; Jun Nakajima
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-06-27

3.  Retrospective assessment of interobserver agreement and accuracy in classifications and measurements in subsolid nodules with solid components less than 8mm: which window setting is better?

Authors:  Roh-Eul Yoo; Jin Mo Goo; Eui Jin Hwang; Soon Ho Yoon; Chang Hyun Lee; Chang Min Park; Soyeon Ahn
Journal:  Eur Radiol       Date:  2016-07-25       Impact factor: 5.315

4.  Pulmonary adenocarcinomas appearing as part-solid ground-glass nodules: is measuring solid component size a better prognostic indicator?

Authors:  Eui Jin Hwang; Chang Min Park; Youngjin Ryu; Sang Min Lee; Young Tae Kim; Young Whan Kim; Jin Mo Goo
Journal:  Eur Radiol       Date:  2014-10-02       Impact factor: 5.315

Review 5.  International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma.

Authors:  William D Travis; Elisabeth Brambilla; Masayuki Noguchi; Andrew G Nicholson; Kim R Geisinger; Yasushi Yatabe; David G Beer; Charles A Powell; Gregory J Riely; Paul E Van Schil; Kavita Garg; John H M Austin; Hisao Asamura; Valerie W Rusch; Fred R Hirsch; Giorgio Scagliotti; Tetsuya Mitsudomi; Rudolf M Huber; Yuichi Ishikawa; James Jett; Montserrat Sanchez-Cespedes; Jean-Paul Sculier; Takashi Takahashi; Masahiro Tsuboi; Johan Vansteenkiste; Ignacio Wistuba; Pan-Chyr Yang; Denise Aberle; Christian Brambilla; Douglas Flieder; Wilbur Franklin; Adi Gazdar; Michael Gould; Philip Hasleton; Douglas Henderson; Bruce Johnson; David Johnson; Keith Kerr; Keiko Kuriyama; Jin Soo Lee; Vincent A Miller; Iver Petersen; Victor Roggli; Rafael Rosell; Nagahiro Saijo; Erik Thunnissen; Ming Tsao; David Yankelewitz
Journal:  J Thorac Oncol       Date:  2011-02       Impact factor: 15.609

6.  Accuracy of CT parameters for assessment of tumour size and aggressiveness in lung adenocarcinoma with bronchoalveolar elements.

Authors:  U N Bhure; D Lardinois; V Kalff; T F Hany; A Soltermann; B Seifert; H C Steinert
Journal:  Br J Radiol       Date:  2010-10       Impact factor: 3.039

7.  Radiomic features from computed tomography to differentiate invasive pulmonary adenocarcinomas from non-invasive pulmonary adenocarcinomas appearing as part-solid ground-glass nodules.

Authors:  Ting Luo; Ke Xu; Zheng Zhang; Lina Zhang; Shandong Wu
Journal:  Chin J Cancer Res       Date:  2019-04       Impact factor: 5.087

Review 8.  Small peripheral lung adenocarcinoma: CT and histopathologic characteristics and prognostic implications.

Authors:  Zhi-gang Chu; Zhi-gang Yang; Heng Shao; Zhi-yu Zhu; Wen Deng; Shi-si Tang; Jing Chen; Yuan Li
Journal:  Cancer Imaging       Date:  2011-12-28       Impact factor: 3.909

9.  Prognostic significance of tumor size of small lung adenocarcinomas evaluated with mediastinal window settings on computed tomography.

Authors:  Yukinori Sakao; Hiroaki Kuroda; Mingyon Mun; Hirofumi Uehara; Noriko Motoi; Yuichi Ishikawa; Ken Nakagawa; Sakae Okumura
Journal:  PLoS One       Date:  2014-11-03       Impact factor: 3.240

10.  Importance of avoiding surgery delays after initial discovery of suspected non-small-cell lung cancer in clinical stage IA patients.

Authors:  Hiroaki Kuroda; Yusuke Sugita; Yuko Ohya; Tatsuya Yoshida; Takaaki Arimura; Noriaki Sakakura; Toyoaki Hida; Yasushi Yatabe; Yukinori Sakao
Journal:  Cancer Manag Res       Date:  2018-12-20       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.